Loading clinical trials...

Barriers to MASLD Management in Europe: Findings From a Multidisciplinary HCP-survey | Clinical Trials | Clareo Health

COMPLETED

Barriers to MASLD Management in Europe: Findings From a Multidisciplinary HCP-survey

NCT05765890•Novo Nordisk A/S

Summary

The purpose of this study is to better understand the main barriers to earlier diagnosis and better management of MASLD/MASH patients and to understand the key barriers to adoption of guidelines. This study is a cross-sectional design, conducted across 5 countries in Europe- France, Germany, Spain, United Kingdom (UK), Italy. Study participants, Hepatologists and other metabolically focused healthcare providers (HCPs), will be recruited to complete a 15 minute self-administered online survey.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•For Hepatologists:
•1. Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
•2. Male or female, age above or equal to 18 years at the time of signing informed consent.
•3. Is a physician
•4. Lives in UK, France, Germany, Italy or Spain
•5. Primary medical specialty is:
•5.a. Hepatology or 5.b. Gastroenterology or Internal Medicine with a subspecialty in Hepatology 6. In practice at least 3 years 7. Spends at least 50 percent of their time in an office/clinic setting 8. Spends at least 60 percent of their time in direct patient care 9. Sees at least 15 patients/month with MASH/MASLD
•For Metabolically-Focused HCPs (Endocrinologist/General Physician/Family Physician/Internal Medicine):
•1. Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
•2. Male or female, age above or equal to 18 years at the time of signing informed consent.
+4 more criteria

Exclusion Criteria

•1. Previous participation in this study. Participation is defined as having given informed consent in this study
•2. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

Locations (1)

Novo Nordisk Investigational Site

Bangalore, India

Key Dates

Start Date

March 24, 2023

Primary Completion Date

September 12, 2023

Completion Date

September 12, 2023

Last Updated

October 11, 2023

Enrollment

675

ACTUAL participants

Conditions

Non-alcoholic Steatohepatitis (MASH)Non-alcoholic Fatty Liver Disease (MASLD)

Interventions

No treatment given

OTHER